Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.42 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812038 | 0.92 | DRD4 (0.44) | CCR3CCR1DRD4ALDH1A1MAPT | |
| SCHEMBL1810524 | 0.91 | CCR3 (0.44) | CCR3CCR1DRD4MAPTCCR2 | |
| SCHEMBL1809975 | 0.86 | CCR3 (0.53) | CCR3CCR1DRD4ALDH1A1KCNH2 | |
| SCHEMBL1809978 | 0.86 | CCR3 (0.53) | CCR3CCR1DRD4ALDH1A1KCNH2 | |
| SCHEMBL1807350 | 0.86 | CCR3 (0.45) | CCR3CCR1DRD4MAPTCCR2 | |
| SCHEMBL1813495 | 0.85 | CCR3 (0.43) | CCR3DRD4ALDH1A1MAPTCCR2 | |
| SCHEMBL1810697 | 0.84 | DRD4 (0.42) | CCR3DRD4CCR2KCNH2SIGMAR1 | |
| SCHEMBL1809273 | 0.84 | CCR3 (0.44) | CCR3CCR1DRD4ALDH1A1MAPT | |
| SCHEMBL1811262 | 0.82 | CCR3 (0.41) | CCR3CCR1DRD4ALDH1A1MAPT | |
| SCHEMBL1808801 | 0.82 | CCR3 (0.43) | CCR3CCR1DRD4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CCR3 1/4885CCR1 2/4885DRD4 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.